FOXA1: a transcription factor with parallel functions in development and cancer

• Published in: Bioscience reports 2012-04, Vol.32 (2), p.113-130
• Main Authors: Bernardo, Gina M, Keri, Ruth A
• Format: Article
• Language: English
• Subjects: Animals; Breast - metabolism; Breast Neoplasms - genetics; Breast Neoplasms - metabolism; Female; Gene Expression Regulation, Developmental; Gene Expression Regulation, Neoplastic; Hepatocyte Nuclear Factor 3-alpha - genetics; Hepatocyte Nuclear Factor 3-alpha - metabolism; Humans; Male; Prostate - metabolism; Prostatic Neoplasms - genetics; Prostatic Neoplasms - metabolism; Receptors, Androgen - metabolism; Receptors, Estrogen - metabolism
• ISSN: 0144-8463; 1573-4935
• DOI: 10.1042/BSR20110046

When aberrant, factors critical for organ morphogenesis are also commonly involved in disease progression. FOXA1 (forkhead box A1), also known as HNF3α (hepatocyte nuclear factor 3α), is required for postnatal survival due to its essential role in controlling pancreatic and renal function. In addition to regulating a variety of tissues during embryogenesis and early life, rescue experiments have revealed a specific role for FOXA1 in the postnatal development of the mammary gland and prostate. Activity of the nuclear hormone receptors ERα (oestrogen receptor α) and AR (androgen receptor) is also required for proper development of the mammary gland and prostate respectively. FOXA1 modulates ER and AR function in breast and prostate cancer cells, supporting the postulate that FOXA1 is involved in ER and AR signalling under normal conditions, and that some carcinogenic processes in these tissues stem from hormonally regulated developmental pathways gone awry. In addition to broadly reviewing the function of FOXA1 in various aspects of development and cancer, this review focuses on the interplay of FOXA1/ER and FOXA1/AR, in normal and cancerous mammary and prostate epithelial cells. Given the hormone dependency of both breast and prostate cancer, a thorough understanding of FOXA1's role in both cancer types is critical for battling hormone receptor-positive disease and acquired anti-hormone resistance.